Clavis Pharma ASA, the Norwegian cancer-drug developer, has appointed Robert Spiegel to its board of directors. He is a medical doctor with long experience in cancer research at Schering-Plough.
Dr Spiegel has also worked in academia. He has held several research positions in the department of medicine at New York University and is currently an associate fellow at the Center for Bioethics at the University of Pennsylvania. He also sits on the board of Geron Corp, Capstone Therapeutics and Talon Therapeutics.
Copyright 2011 Evernow Publishing Ltd